Breast cancer biomarkers and molecular medicine: Part II

Expert Review of Molecular Diagnostics

Volumn 4, Issue 2, 2004, Pages 169-188

  Ross, Jeffrey S ^a,b   Linette, Gerald P ^b,c   Stec, James ^b   Clark, Edwin ^b   Ayers, Mark ^b   Leschly, Nick ^b   Symmans, W Fraser ^d   Hortobagyi, Gabriel N ^d   Pusztai, Lajos ^d  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Breast cancer; ER; Heat shock proteins; Matrix metalloproteases; MDR; Microarrays; Oncogenes; P53; Pharmacogenetics; Pharmacogenomics; Plasminogen; PR proteases; Prognosis; Telomerase; Transcriptional profiling; Tumor suppressor genes

Indexed keywords

AMONAFIDE; ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; AZACITIDINE; BEVACIZUMAB; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EXEMESTANE; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; IRINOTECAN; LETROZOLE; MARIMASTAT; MATRIX METALLOPROTEINASE; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN 1; OBLIMERSEN; PACLITAXEL; PROTEASOME INHIBITOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; DISEASE MARKER; DNA BINDING; DNA METHYLATION; DNA MICROARRAY; DNA REPAIR; DRUG TARGETING; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENE THERAPY; HUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PHARMACOGENETICS; PROGNOSIS; PROTEIN DNA BINDING; PROTO ONCOGENE; REVIEW; SIDE EFFECT; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL ADHESION MOLECULES; DNA; DRUG RESISTANCE, MULTIPLE; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; PHARMACOGENETICS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TELOMERASE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 1542358118     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.4.2.169     Document Type: Review

References (236)

1. Ross JS, Linette GP, Stec J et al. Breast cancer biomarkers and molecular medicine. Expert Rev. Mol. Diagn. 3, 573-585 (2003).
2. Deming SL, Nass SJ, Dickson RB et al. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br. J. Cancer 83, 1688-1695 (2000).
3. Mizukami Y, Nonomura A, Takizawa T et al. N-myc protein expression in human breast carcinoma: prognostic implications. Anticancer Res. 15, 2899-2905 (1995).
4. Schlotter CM, Vogt U, Bosse U et al. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res. 5, R30-R36 (2003).
5. Rochlitz CF, Scott GK, Dodson JM et al. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res. 49, 357-360 (1989).
6. Schondorf T, Andrack A, Niederacher D et al. H-ras gene amplification or mutation is not common in human primary breast cancer. Oncol. Rep. 6, 1029-1033 (1999).
7. Bland KI, Konstadoulakis MM, Vezeridis MP et al. Oncogene protein coexpression. Value of H-ras, c-myc, c-fos and p53 as prognostic discriminants for breast carcinoma. Ann. Surg. 221, 706-720 (1995).
8. Guerin M, Sheng ZM, Andrieu N et al. Strong association between c-myb and estrogen-receptor expression in human breast cancer. Oncogene 5, 131-135 (1990).
9. Gee JM, Ellis IO, Robertson JF et al. Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy, Int. J. Cancer 64, 269-273 (1995).
10. Esteva FJ, Sahin AA, Rassidakis GZ et al. Jun activation domain binding protein 1 expression is associated with low p27(Kip1) levels in node-negative breast cancer. Clin. Cancer Res. 9, 5652-5659 (2003).
11. Gee JM, Barroso AF, Ellis IO et al. Biological and clinical associations of c-jun activation in human breast cancer. Int. J. Cancer 89, 177-186 (2000).
12. Kouvaraki MA, Rassidakis GZ, Tian L et al. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res. 63, 2977-2981 (2003).
13. Liu MC, Gelmann, EP. p53 gene mutations: case study of a clinical marker for solid tumors. Semin. Oncol. 29, 246-257 (2002).
14. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res. 4, 70-76 (2002). Overview of p53 status and correlation with other parameters.
15. Lohmann D, Ruhri C, Schmitt M et al. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Diagn. Mol. Pathol. 2, 36-41 (1993).
16. Bhargava V, Thor A, Deng G et al. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod. Pathol. 7, 361-368 (1994).
17. Soussi T, Beroud C. Assessing TP53 status in human tumors to evaluate clinical outcome. Nature Rev. Cancer 1, 233-240 (2001). Thorough review of p53 testing in clinical samples: cautions against the use of immunohistochemistry (IHC).
18. Borresen-Dale AL. TP53 and breast cancer. Hum. Mutat. 21, 292-300 (2003).
19. Thor AD, Moore DH, Edgerron SM et al. p53 tumor suppressor gene: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst. 84, 845-855 (1992).
20. Cunningham JM, Ingle JN, Jung SH et al. p53 gene expression in node positive breast cancer relationship to DNA ploidy and prognosis. J. Natl Cancer Inst. 86, 1871-1873 (1994).
21. Caleffi M, Teague MW, Jensen RA et al. p53 gene mutations and steroid receptor status in breast carcinoma. Clinical pathologic correlations and prognostic assessment. Cancer 73, 2147-2156 (1994).
22. Marks JR, Humphrey PA, Wu K et al. Overexpression of p53 and Her-2/neu proteins as prognostic markers in early stage breast cancer. Ann. Surg. 219, 332-341 (1994).
23. Beck T, Weller EE, Weikel W et al. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlation with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol. Oncol. 57, 96-104 (1995).
24. Borg A, Lennerstand J, Stenmark-Askmalm M et al. Prognostic significance of p53 overexpression in primary breast cancer: a novel luminometric immunoassay applicable on steroid receptor cytosols. Br. J. Cancer 71, 1013-1017 (1995).
25. Bland KI, Konstadoulakis MM, Vezeridis MP et al. Oncogene protein co-expression. Value of H-ras, c-myc, c-fos and p53 as prognostic discriminants for breast carcinoma. Ann. Surg. 221, 706-718 (1995).
26. Peyrat J-P, Bonneterre J, Lubin R et al. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for local regional breast cancer. Lancet 345, 621-622 (1995).
27. Katoh A, Breier S, Stemmler N et al. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease. Anticancer Res. 16, 1301-1304 (1996).
28. Soong R, Iacopetta BJ, Harvey JM et al. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Clin. Cancer Res. 6, 443-451 (2000).
29. Clahsen PC, van de Velde CJ, Duval C et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J. Clin. Oncol. 16, 470-479 (1998).
30. Rozan S, Vincent-Salomon A, Zafrani B et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer 79, 27-33 (1998).
31. Peyrat JP, Vanlemmens L, Fournier et al. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers. Clin. Cancer Res. 4, 189-196 (1998).
32. Levesque MA, Yu H, Clark GM, Diamandis EP. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. J. Clin. Oncol. 16, 2641-2650 (1998).
33. Jansen RL Joosten-Achjanie SR, Volovics A et al. Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer. Anticancer Res. 18, 4455-4462 (1998).
34. Harbeck N, Dettmar P, Thomssen C et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br. J. Cancer 80, 419-426 (1999).
35. Broet P, Spyratos F, Romain S et al. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study. Br. J. Cancer 80, 536-545 (1999).
36. Reed W, Hannisdal E, Boehler PJ et al. The prognostic value of p53 and c-erb Bcl-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 88, 804-813 (2000).
37. Berns EM, Foekens JA, Vossen R et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 60, 2155-2162 (2000).
38. Ferrero JM, Ramaioli A, Formento JL et al. P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann. Oncol. 11, 393-397 (2000).
39. Bottini A, Berruti A, Bersiga A et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin. Cancer Res. 6, 2751-2758 (2000).
40. Geisler S, Lonning PE, Aas T et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61, 2505-2512 (2001).
41. Montero S, Guzman C, Vargas C et al. Prognostic value of cytosolic p53 protein in breast cancer. Tumour Biol 22, 337-344 (2001).
42. Tsutsui S, Ohno S, Murakam S et al. Prognostic value of p53 protein expression in breast cancer an immunohistochemical analysis of frozen sections in 514 Japanese women. Breast Cancer 8, 194-201 (2001).
43. O'Hanlon DM, Kiely M, MacConmara M et al. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma. Eur J. Surg. Oncol. 28, 103-107 (2002).
44. Shao ZM, Wu J, Shen ZZ et al. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin. Cancer Res. 7, 2222-2227 (2001).
45. Kato T, Kameoka S, Kimura T et al. p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. Anticancer Res. 22, 1105-1112 (2002).
46. Tahan SR, Neuberg DS, Dieffenbach A et al. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 71, 3552-3559 (1993).
47. Chen HH, Su WC, Guo HR et al. p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan. Jpn. J. Clin. Oncol. 32, 332-339 (2002).
48. Lohmann D, Ruhri C, Schmitt M et al. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Diagn. Mol. Pathol. 2, 36-41 (1993).
49. Bhargava V, Thor A, Deng G et al. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod. Pathol. 7, 361-368 (1994).
50. Rosanelli GP, Steindorfer P, Wirnsberger GH et al. Mutant p53 expression and DNA analysis in human breast cancer. Comparison with conventional clinicopathological parameters. Anticancer Res. 15, 581-586 (1995).
51. Pelosi G, Bresaola E, Rodella S et al. Expression of proliferating cell nuclear antigen, Ki-67 antigen, estrogen receptor protein and tumor suppressor p53 gene in cytologic samples of breast cancer: an immunochemical study with clinical, pathobiological, and histologic correlations. Diagn. Cytopathol. 11, 131-140 (1994).
52. Daidone MG, Veneroni S, Benini E et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int. J. Cancer 84, 580-586 (1999).
53. Kandioler-Eckersberger D, Ludwig C, Rudas M et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 6, 50-56 (2000).
54. Bertheau P, Plassa F, Espie M et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360, 852-854 (2002).
55. Sjostrom J, Blomqvist C, Heikkila P et al. Predictive value of p53, mdm-2, p21 and mib-1 for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 6, 3103-3110 (2000).
56. Van Poznak C, Tan L, Panageas KS et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J. Clin. Oncol. 20, 2319-2926 (2002).
57. Hamilton A, Larsiniont D, Paridaens R et al. A study of the value of p53, HER2 and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin. Breast Cancer 1, 233-240 (2000).
58. Knoop AS, Bentzen SM, Nielsen MM et al. Value of epidermal growth factor receptor, HER2, p53 and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J. Clin. Oncol. 19, 3376-3384 (2001).
59. Quesnel B, Preudhomme C, Fournier J et al. MDM2 gene amplification in human breast cancer. Eur. J. Cancer 30A, 982-984 (1994).
60. McCann AH, Kirley A, Carney DN et al. Amplification of the MDM2 gene in human breast cancer and its association with MDMp53 protein status. Br. J. Cancer 71, 981-985 (1995).
61. Bueso-Ramos CE, Manshouri T, Haidar MA et al.Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat. 37, 179-188 (1996).
62. Jiang M, Shao ZM, Wu J et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer 74, 529-534 (1997).
63. Mathoulin-Portier MP, Viens P, Cowen D et al. Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with anthracycline. Oncol. Rep. 7, 675-680 (2000).
64. Cuny M, Kramar A, Courjal F et al. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 60, 1077-1083 (2000).
65. Bankfalvi A, Tory K, Kemper M et al. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol. Res. Pract. 196, 489-501 (2000).
66. Benedict WF, Xu H-J, Takahashi R. The retinoblastoma gene: its role in human malignancies. Cancer Invest. 8, 535-540 (1990).
67. Varley JM, Armour J, Swallow JE et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumors. Oncogene 4, 725-729 (1989).
68. Berns EM, de Klein A, van Putten WL et al. Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival. Int. J. Cancer 64, 140-145 (1995).
69. Postel EH. NM23-NDP kinase. Int. J. Biochem. Cell. Biol. 30, 1291-1295 (1998).
70. Duenas-Gonzalez A, Abad-Hernandez MM, Garcia-Mata J et al. Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings. Cancer Lett. 101, 137-142 (1996).
71. Mao H, Liu H, Fu X et al. Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer. Int. J. Oncol. 18, 587-591 (2001).
72. Terasaki-Fukuzawa Y, Kijima H, Suto A et al. Decreased nm23 expression but not Ki-67 labeling index, is significantly correlated with lymph node metastasis of breast invasive ductal carcinoma. Int. J. Mol. Med 9, 25-29 (2002).
73. Gohring UJ, Eustermann I, Becker M et al. Lack of prognostic significance of nm23 expression in human primary breast cancer. Oncol. Rep. 9, 1205-1208 (2002).
74. Belev B, Aleric I, Vrbanec D et al. Nm23 gene product expression in invasive breast cancer: immunohistochemical analysis and clinicopathological correlation. Acta Oncol 41, 355-361 (2002).
75. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell. Mol. Life Sci. 58, 1907-1922 (2001).
76. Sherr CJ. The INK4a/ARF network in tumour suppression. Nature Rev. Mol. Cell. Biol. 2, 731-737 (2001).
77. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21, 5427-5440 (2002).
78. Hui R, Macmillan RD, Kenny FS et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin. Cancer. Res. 6, 2777-2787 (2000).
79. Han S, Ahn SH, Park K et al. P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Breast Cancer Res. Treat. 70, 205-212 (2001).
80. Milde-Langosch K, Bamberger AM, Rieck G et al. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res. Treat. 67, 61-70 (2001).
81. Ito Y, Kobayashi T, Takeda T et al. Expression of p16 and cyclin-dependent kinase 4 proteins in primary breast carcinomas. Oncology 54, 508-515 (1997).
82. Span PN, Manders P, Heuvel JJ et al. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 21, 8506-8509 (2002).
83. Mills GB, Lu Y, Fang X et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis and therapy. Semin. Oncol. 28, 125-141 (2001).
84. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 27, 462-467 (2002).
85. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 14, 672-676 (2001).
86. Maas N, Teffner M, Rosel F et al. Decline in the expression of the serine proteinase inhibitor maspin is associated with tumor progression in ductal carcinomas of the breast. J. Pathol. 195, 321-326 (2001).
87. Umekita Y, Ohi Y, Sagara Y et al. Expression of maspin predicts poor prognosis in breast cancer patients. Int. J. Cancer 100, 452-455 (2002).
88. Corradini P, Voena C, Astolfi M et al. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann. Oncol. 12, 1693-1698 (2001).
89. Mohsin SK, Zhang M, Clark GM et al. Maspin expression in invasive breast cancer association with other prognostic factors. J. Pathol 199, 432-435 (2003).
90. Wei M, Grushko T, Hagos F et al. Hypermethylation of BRCA1 promoter in sporadic breast cancer: comparison with BRCA1 associated breast cancer. Breast Cancer Res. Treat. 76(Suppl. 1), S35 (2002) (Abstract 26).
91. Ohene-Abuakwa Y, Pignatelli M. Adhesion molecules in cancer biology. Adv. Exp. Med. Biol. 465, 115-126 (2000). Overview of cell adhesion molecule biology in cancer and potential roles in invasion and metastasis.
92. Skubitz AP. Adhesion molecules. Cancer Treat. Res. 107, 305-329 (2002).
93. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 3, 289-293 (2001).
94. Barker N, Clevers H. Catenins, Wnt signaling and cancer. Bioassays 22, 961-965 (2000).
95. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin/catenin cell-cell adhesion complex and human cancer. Br. J. Surg. 87, 992-1005 (2000).
96. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur. J. Cancer 36, 1607-1620 (2000).
97. Charpin C, Garcia S, Bonnier P et al. Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am. J. Clin. Pathol 109, 431-438 (1998).
98. Parker C, Rampaul RS, Pinder SE et al. E-cadherin as a prognostic indicator in primary breast cancer. Br. J. Cancer 85, 1958-1963 (2001).
99. Yoshida R, Kimura N, Harada Y et al. The loss of E-cadherin, α- and β-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int. J. Oncol. 18, 513-520 (2001).
100. Gillett CE, Miles DW, Ryder K et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J. Pathol. 193, 433-441 (2001).
101. Cheng CW, Wu PE, Yu JC et al. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20, 3814-3823 (2001).
102. Reis-Filho JS, Cancela Paredes J, Milanezi F et al. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 94, 2114-2115 (2002).
103. Chan JK, Wong CS. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv. Anat. Pathol. 8, 165-172 (2001).
104. Kleer CG, van Golen KL, Braun T et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod. Pathol. 14, 458-464 (2001).
105. Burguignon LY. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J. Mammary Gland Biol. Neoplasia 6, 287-297 (2001).
106. Joensuu H, Klemi PJ, Toikkanen S et al. Glycoprotein CD44 expression and its association with survival in breast cancer. Am. J. Pathol. 143, 866-874 (1993).
107. Foekens JA, Dall P, Klijn JG et al. Prognostic value of CD44 variant expression in primary breast cancer. Int. J. Cancer 84, 209-215 (1999).
108. Guriec N, Gairard B, Marcellin L et al. CD44 isoforms with exon v6 and metastasis of primary N0M0 breast carcinomas. Breast Cancer Res. Treat. 44, 261-268 (1997).
109. Schumacher U, Horny HP, Horst HA et al. A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer. Eur. J. Surg. Oncol. 22, 259-261 (1996).
110. Morris SF, O'Hanlon DM, McLaughlin R et al. The prognostic significance of CD44s and CD44v6 expression in Stage II breast carcinoma: an immunohistochemical study. Eur. J. Surg. Oncol. 27, 527-531 (2001).
111. Jansen RH, Joosten-Achjanie SR, Arends JW et al. CD44v6 is not a prognostic factor in primary breast cancer. Ann. Oncol 9, 109-111 (1998).
112. Sheen-Chen SM, Chen WJ, Eng HL et al. Evaluation of the prognostic value of serum soluble CD44 in patients with breast cancer. Cancer Invest. 17, 581-585 (1999).
113. Kopp R, Classen S, Wolf H et al. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res. 21, 2995-3000 (2001).
114. Ivaska J, Heino J. Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell. Mol. Life Sci. 57, 16-24 (2000).
115. Marques LA, Franco ELF, Tortoni H et al. Independent prognostic value on laminin receptor expression in breast cancer survival. Cancer Res. 50, 1479-1483 (1990).
116. D-Errico A, Garbisa S, Liotta LA et al. Augmentation of Type IV collagenase laminin receptor and ki67 proliferation antigen associated with human colon, gastric and breast carcinoma progression. Mod. Pathol. 4, 239-246 (1991).
117. Daidone MG, Silvestrini R, D'Errico A et al. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int. J. Cancer 48, 529-532 (1991).
118. D-Errico A, Garbisa S, Liotta LA et al. Augmentation of Type IV collagenase laminin receptor and ki67 proliferation antigen associated with human colon, gastric and breast carcinoma progression. Mod. Pathol. 4, 239-246 (1991).
119. Gasparini G, Brooks PC, Biganzoli E et al. Vascular integrin α(v)β3, a new prognostic indicator in breast cancer. Clin. Cancer Res. 4, 2625-2634 (1998).
120. Tagliabue E, Ghirelli C, Squicciarini P et al. Prognostic value of α6β4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin. Cancer Res. 4, 407-410 (1998).
121. Friedrichs Y, Ruiz P, Franke F et al. High expression level of α6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res. 55, 901-906 (1995).
122. Gastl G, Spizzo G, Obrist P et al. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356, 1981-1982 (2000).
123. Braun S, Pantel K. Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res. Treat. 52, 201-216 (1998).
124. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit. Rev. Oncol. Hematol. 40, 17-24 (2001).
125. Rochefort H, Chalbos D, Cunat S et al. Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J. Steroid. Biochem. Mol. Biol. 76, 119-124 (2001).
126. Thorpe SM, Rocheford H, Garcia M et al. Association between high concentration of M52,000 cathepsin D and poor prognosis in primary breast cancer. Cancer Res. 49, 6008-6014 (1989).
127. Tandon AK, Clank GM, Chamness GC et al. Cathepsin D and prognosis in breast cancer. N. Engl. J. Med. 322, 297-302 (1990). Initial interest in cathepsin D testing faded when it became clear that the assay was only useful when performed on fresh tissue or protein extracts.
128. Kute TE, Shao ZM, Sugg NK et al. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res. 52, 5198-5203 (1992).
129. Henry JA, McCarthy AI, Angus B et al. Prognostic significance of the estrogen regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 65, 265-271 (1990).
130. Visscher DW, Sarkar F, LoRusso P et al. Immunohistologic evaluation on invasion-associated proteases in breast carcinoma. Mod. Pathol. 6, 302-306 (1993).
131. Mokbel K, Elkak A. Recent advances in breast cancer (the 37th ASCO meeting, May 2001). Curr. Med. Res. Opin. 17, 116-122 (2001).
132. Harbeck N, Schmitt M, Kates RE et al. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin. Breast Cancer 3, 196-200 (2002).
133. Harbeck N, Kates RE, Look MP et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 62, 4617-4622 (2002).
134. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin. Chem. 48, 1194-1197 (2002).
135. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J. Clin. Oncol. 20, 1000-1007 (2002). The plasminogen proteases are reliable and accurate prognostic factors, but are limited by their current requirement for fresh protein extracts for testing.
136. Qin W, Zhu W, Wagner-Mann C. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Ann. Surg. Oncol. 10, 948-953 (2003).
137. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161-74 (2002).
138. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nature Rev. Mol. Cell. Biol. 3, 207-214 (2002).
139. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol. Med. Today 6, 149-156 (2000).
140. Benaud C, Dickson RB, Thompson EW. Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res. Treat. 50, 97-116 (1998).
141. Porter-Jordan K, Hoyhtya M, Barnes R et al. Prognostic value of the level of matrix metalloprotease-2 in the fibroblasts surrounding infiltrating ductal carcinoma of the breast. Breast Cancer Res. Treat 23, 149 (1992).
142. Talvensaari-Mattila A, Paakko P, Hoyhtya M et al. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83, 1153-1162 (1998).
143. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res. Treat. 58, 287-293 (1999).
144. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G et al. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with anti-estrogen adjuvant therapy. Breast Cancer Res. Treat. 65, 55-61 (2001).
145. Pacheco MM, Nishimoto IN, Mourao Neto M et al. Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by northern blot analysis. Int. J. Biol. Markers 16, 62-68 (2001).
146. Scorilas A, Karameris A, Arnogiannaki N et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer 84, 1488-1496 (2001).
147. Chenard MP, O'Siorain L, Shering S et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer 69, 448-451 (1996).
148. McCarthy K, Maguire T, McGreal G et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int. J. Cancer 84, 44-48 (1999).
149. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther. 75, 69-75 (1997).
150. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 51, 227-238 (1998).
151. Locker GY. Hormonal therapy of breast cancer. Cancer Treat. Rev. 24, 221-240 (1998).
152. Pusztai L, Ayers M, Stec J et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin. Cancer Res. 9, 2406-2415 (2003).
153. Masood S. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers. Surg. Oncol. Clin. N. Am 4, 601-632 (1995).
154. Wilbur DC, Willis J, Mooney RA et al. Estrogen and progesterone detection in archival formalin-fixed paraffin embedded tissue from breast carcinoma: a comparison of immunocytochemistry with dextran coated charcoal assay. Mod. Pathol. 5, 79-84 (1992).
155. Bezwoda WR, Esser JD, Dansey R et al. The value of estrogen progesterone receptor determinations in advanced breast cancer. Cancer 68, 867-872 (1991).
156. Lemieux P, Fuqua S. The role of the estrogen receptor in tumor progression. J. Steroid Biochem. Mol. Biol. 56, 87-91 (1996).
157. Clemons M, Danson S, Howell A. Tamoxifen ('Nolvadex'): a review. Cancer Treat. Rev. 28, 165-180 (2002).
158. Ciocca DF, Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13, 1-10 (2000).
159. Ibrahim NK, Hortobagyi GN. The evolving role of specific estrogen receptor modulators (SERMs). Surg. Oncol. 8(2), 103-123 (1999).
160. Miller WR, Anderson TJ, Dixon JM. Antitumor effects of letrozole. Cancer Invest. 20, 15-21 (2002).
161. Buzdar AU, Robertson JF, Eiermann W et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 95, 2006-20016 (2002).
162. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol. 19, 3808-3816 (2001). The concept that HER-2/neu status can predict response to specific antiestrogen therapy is considered.
163. Dowsett M, Harper-Wynne C, Boeddinghaus I et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 61, 8452-8458 (2001).
164. Decker DA, Morris LW, Levine AJ et al. Multi-drug resistance phenotype: a potential marker of chemotherapy resistance in breast cancer. Lab. Med. 24, 574-578 (1993).
165. Wang CS, LaRue H, Fortin A et al. mdR1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res. Treat. 45, 63-74 (1997).
166. Trock BJ, Leonessa F, Clarke R. Multi-drug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl Cancer Inst. 89, 917-931 (1997).
167. Batiste G, Tulpule A, Shinha BK et al. Overexpression of a novel and an ionic glutathionic transferase in multi-drug-resistant human breast cancer cells. J. Biol. Chem. 261, 15554-15549 (1986).
168. Satta T, Isobe K, Yamauchi M et al. Expression of MDR1 and gluthathione s-transferase genes and chemosensitivities in human gastrointestinal cancer. Cancer 69, 941-946 (1992).
169. Ardavanis A, Gerakini F, Amanatidou A et al. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance. Anticancer Res. 17, 3665-3669 (1997).
170. Dittadi R, Biganzoli E, Boracchi P et al. Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen. Int. J. Biol. Markers 13, 30-41 (1998).
171. Fuqua SA, Oesterreich S, Hilsenbeck SG et al. Heat shock proteins and drug resistance. Breast Cancer Res. Treat. 32, 67-71 (1994).
172. Chamness GC. Estrogen-inducible heat shock protein hsp27 predicts recurrence in node-negative breast cancer. Proc. Am. Assoc. Cancer Res. 30, 252 (1989).
173. Ciocca DR, Clark GM, Tandon AK et al. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst. 85, 570-574 (1993).
174. Tetu B, Brisson J, Landry J et al. Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study. Breast Cancer Res. Treat. 36, 93-97 (1995).
175. Oesterreich S, Hilsenbeck SG, Ciocca DR et al. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 2, 1199-1206 (1996).
176. Parton M, Dowsert M, Smith I. Studies of apoptosis in breast cancer. Br. Med. J. 322, 1528-1532 (2001).
177. Berardo MD, Elledge RM, de Moor C et al. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 82, 1296-1302 (1998).
178. Zhang GJ, Kimijima I, Abe R et al. Apoptotic index correlates to Bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res. 18, 1989-1998 (1998).
179. De Jong JS, van Diest PJ, Baak JP. Number of apoptotic cells as a prognostic marker in invasive breast cancer. Br. J. Cancer 82, 368-373 (2000).
180. Gonzalez-Campora R, Galera Ruiz MR, Vazquez Ramirez F et al. Apoptosis in breast carcinoma. Pathol. Res. Pract. 196, 167-174 (2000).
181. Krajewski S, Krajewska M, Turner BC et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr. Relat. Cancer 6, 29-40 (1999).
182. Yang Q, Sakurai T, Yoshimura G et al. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol. Rep. 10, 121-125 (2003).
183. L, bag-1, fas and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 8, 811-816 (2002).
184. Vakkala M, Paakko P, Soini Y. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion. Br. J. Cancer 81, 592-599 (1999).
185. Nakopoulou L, Alexandrou P, Stefanaki K et al. Immunohistochemical expression of caspase-3 as an adverse indicator of the clinical outcome in human breast cancer. Pathobiology 69, 266-273 (2001).
186. Devarajan E, Sahin AA, Chen JS et al. Downregulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 21, 8843-8851 (2002).
187. Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights. Ann. Rev. Immunol. 14, 649-683 (1996).
188. Orlowski RZ, Baldwin AS. NF-κB as a therapeutic target in cancer. Trends Mol. Med. 8(8), 385-389 (2002).
189. Karin M, Cao Y, Greten FR et al. NF-κB in cancer from innocent bystander to major culprit. Nature Rev. Cancer 2, 301-310, (2002).
190. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr. Opin. Chem. Biol. 6, 493-500 (2002).
191. Biswas DK, Dai SC, Cruz A et al. The nuclear factor κB (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl Acad. Sci. USA 98, 10386-10391 (2001).
192. Span PN, Manders P, Heuvel JJ et al. Expression of the transcription factor Ets-1 is an independent prognostic marker market for relapse-free survival in breast cancer. Oncogene 21, 8506-8509 (2002).
193. Jonsson M, Dejmek J, Bendahl PO et al. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 62, 409-416 (2002).
194. Herbert BS, Wright WE, Shay JW. Telomerase and breast cancer. Breast Cancer Res. 3, 146-149 (2001).
195. Carey LA, Kim NW, Goodman S et al. Telomerase activity and prognosis in primary breast cancers. J. Clin. Oncol. 17, 3075-3081 (1999).
196. Mokbel K, Parris CN, Radbourne R et al. Telomerase activity and prognosis in breast cancer. Eur. J. Surg. Oncol. 25, 269-272 (1999).
197. Mueller C, Riese U, Kosmehl H et al. Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome. Int. J. Oncol. 20, 385-390 (2002).
198. Bieche I, Nogues C, Paradis V et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6, 452-429 (2000).
199. Poremba C, Heine B, Diallo R et al. Telomerase as a prognostic marker in breast cancer high-throughput tissue microarray analysis of hTERT and hTR. J. Pathol. 198, 181-189 (2002).
200. Andrew SE, Peters AC. DNA instability and human disease. Am. J. Pharmacogenomics 1, 21-28 (2001).
201. Ozer E, Yuksel E, Kizildag S et al. Microsatellite instability in early-onset breast cancer. Pathol. Res. Pract. 198, 525-530 (2002).
202. Tomita S, Deguchi S, Miyaguni T et al. Analyses of microsatellite instability and the transforming growth factor-β receptor Type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features. Breast Cancer Res. Treat. 53, 33-39 (1999).
203. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 21, 5462-5482 (2002).
204. Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr. Relat. Cancer 8, 115-127 (2001).
205. Yang X, Phillips DL, Ferguson AT et al. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res. 61, 7025-7029 (2001).
206. Platt-Higgins AM, Renshaw CA, West CR et al. Comparison of the metastasis-inducing protein S 100A4 (p9ka) with other prognostic markers in human breast cancer. Int. J. Cancer 89, 198-208 (2000).
207. Xu Y, Kimura N, Yoshida R et al. Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors. Oncol. Rep. 8, 1177-1182 (2001).
208. Ristimaki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62, 632-635 (2002).
209. Luftner D, Possinger K. Nuclear matrix proteins as biomarkers for breast cancer. Expert Rev. Mol. Diagn. 2, 23-31 (2002).
210. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94, 1914-1918 (1997).
211. Kayalar R, Sarcevic B, Spagnoli GC et al. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Arch. 439, 127-131 (2001).
212. Otte M, Zafrakas M, Riethdorf L et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res. 61, 6682-6687 (2001).
213. Miyashiro I, Kuo C, Huynh K et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin. Chem. 47, 505-512 (2001).
214. Bertucci F, Houlgatte R, Benziane A et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum. Mol. Genet. 9, 2981-2991 (2000).
215. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad Sci. USA 98, 10869-10874 (2001). Initial discovery study of gene expression and breast cancer biology.
216. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002). Transcriptional profiting of breast cancers with long-term follow-up links patterns of gene expression with overall and disease-free survival.
217. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002). Further details and expansion of data of clinical outcome study.
218. West M, Blanchette C, Dressman H et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl Acad. Sci. USA 98, 11462-11467 (2001).
219. Nevins JR, Huang ES, Dressman H et al. Towards integrated clinico-genomic models for personalized medicine combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum. Mol. Genet. 12, 153-157 (2003).
220. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003).
221. Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene 22, 6497-6507 (2003).
222. Huang E, Cheng SH, Dressman H et al. Gene expression predictors of breast cancer outcomes. Lancet 361, 1590-1596 (2003).
223. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002). Can barcode surface-enhanced laser desorption ionization-based proteomics with neural network data analysis detect occult cancer in serum far earlier than currently available cancer detection methods?
224. Li J, Zhang Z, Rosenzweig J et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296-1304 (2002).
225. Taylor JG. Using genetic variation to study human disease. Trends Mol. Med. 7, 507-512 (2001).
226. Weber W, Estoppey J, Stoll H. Familial cancer diagnosis. Anticancer Res. 21, 3631-3635 (2001).
227. Ingdman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat. Res. 482, 11-19 (2001).
228. Innocenti F, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. Eur. J. Cancer 38, 639-644 (2002).
229. Roses AD. Pharmacogenetics. Hum. Mol. Genet. 10, 2261-2267 (2001).
230. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev. Cancer 1, 99-108 (2001).
231. Nishimura R, Nagao K, Miyayama H et al. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res. 19, 5621-5626 (1999).
232. Weinstein JN. Pharmacogenomics: teaching old drugs new tricks. N. Engl. J. Med. 343, 1408-1409 (2000).
233. Slonim DK. Transcriptional profiling in cancer the path to clinical pharmacogenomics. Pharmacogenomics 2, 123-136 (2001).
234. Ayers M, Symmans WF, Stec J et al. Gene expression profiling of fine needle aspirations of breast cancer identifies genes associated with complete pathologic response to neoadjuvant taxol/FAC chemotherapy. J. Clin. Oncol. (2004) (In Press). First demonstration of the use of transcriptional profiling to predict the response to multiagent breast cancer chemotherapy in the neoadjuvant setting using pathologic complete response as the study end point.
235. Chang JC, Wooten EC, Tsimelzon et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
236. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat. Rev. 29(5), 407-415 (2003).